Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis

Walter Masson; Martín Lobo; Juan Patricio Nogueira; Alfredo Matias Rodriguez-Granillo; Leandro Ezequiel Barbagelata; Daniel Siniawski

doi:10.3389/fcvm.2024.1379189

journal article Open Access Jul 05, 2024

Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis

Walter Masson

Martín Lobo Juan Patricio Nogueira Alfredo Matias Rodriguez-Granillo Leandro Ezequiel Barbagelata Daniel Siniawski

Frontiers in Cardiovascular Medicine Vol. 11 · Frontiers Media SA

View at Publisher Save 10.3389/fcvm.2024.1379189

Abstract

BackgroundThe anti-inflammatory effect could be one of the mechanisms by which semaglutide reduces cardiovascular risk in patients with type 2 diabetes mellitus (T2DM) and/or obesity. Determining the anti-inflammatory effect of semaglutide was the objective of this systematic review and meta-analysis.MethodsThis meta-analysis was performed according to the PRISMA guidelines. A literature search was performed to detect randomised clinical trials that have quantified the effect of semaglutide on C-reactive protein (CRP) levels compared to placebo or a control group (other glucose-lowering drugs). The primary outcome was CRP index (final CRP/basal CRP). A random-effects model was used.ResultsThirteen randomised clinical trials were considered eligible (n = 26,131). Overall, semaglutide therapy was associated with lower CRP index values compared to the placebo group (SMD −0.56; 95% CI −0.69 to −0.43, I2 92%) or the control group (SMD −0.45; 95% CI −0.68 to −0.23, I2 82%).Such an association was similarly observed when different treatment regimens (subcutaneous vs. oral) or different populations (patients with or without T2DM) were analysed. The sensitivity analysis showed that the results were robust.ConclusionThe present meta-analysis demonstrated that the use of semaglutide was associated with a reduction in inflammation irrespective of the population evaluated or the treatment regimen used. These findings would explain one of the mechanisms by which semaglutide reduces cardiovascular events.Systematic Review RegistrationPROSPERO [CRD42024500551].

Topics

No keywords indexed for this article. Browse by subject →

References

64

[1]

Parab "Role of glucagon-like peptide-1 (GLP-1) receptor agonists in cardiovascular risk management in patients with type 2 diabetes mellitus: a systematic review" Cureus (2023) 10.7759/cureus.45487

[2]

Patti "Impact of glucose-lowering medications on cardiovascular and metabolic risk in type 2 diabetes" J Clin Med (2020) 10.3390/jcm9040912

[3]

Patti "Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: an 8-month prospective study" Diabetes Res Clin Pract (2019) 10.1016/j.diabres.2019.02.006

[4]

Guo "Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes" Diabetes Obes Metab (2023) 10.1111/dom.15043

[5]

Giglio "Novel therapeutical approaches to managing atherosclerotic risk" Int J Mol Sci (2021) 10.3390/ijms22094633

[6]

2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes

Nikolaus Marx, Massimo Federici, Katharina Schütt et al.

European Heart Journal 2023 10.1093/eurheartj/ehad192

[7]

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso, Stephen C. Bain, Agostino Consoli et al.

New England Journal of Medicine 2016 10.1056/nejmoa1607141

[8]

Gouveri "Potential new therapeutic implications of semaglutide: new colours of the rainbow?" Diabetes Ther (2023) 10.1007/s13300-023-01506-1

[9]

Amaro "Efficacy and safety of semaglutide for weight management: evidence from the STEP program" Postgrad Med (2022) 10.1080/00325481.2022.2147326

[10]

Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes

A. Michael Lincoff, Kirstine Brown-Frandsen, Helen M. Colhoun et al.

New England Journal of Medicine 2023 10.1056/nejmoa2307563

[11]

Morales "Practical guidance for use of oral semaglutide in primary care: a narrative review" Postgrad Med (2020) 10.1080/00325481.2020.1788340

[12]

Boczar "Hearts on fire: the role of inflammation in the pathogenesis of atherosclerotic cardiovascular disease and how we can tend to the flames" Can J Cardiol (2022) 10.1016/j.cjca.2022.05.023

[13]

Spranger "Inflammatory cytokines and the risk to develop type 2 diabetes—results of the prospective population-based European prospective investigation into cancer and nutrition (EPIC)-Potsdam study" Diabetes (2003) 10.2337/diabetes.52.3.812

[14]

Xu "C-reactive protein and cardiovascular disease in people with diabetes: high-sensitivity CRP testing can help assess risk for future cardiovascular disease events in this population" Am J Nurs (2006) 10.1097/00000446-200608000-00027

[15]

C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus

Aruna D. Pradhan

JAMA 2001 10.1001/jama.286.3.327

[16]

Balogh "An overview of the cardioprotective effects of novel antidiabetic classes: focus on inflammation, oxidative stress, and fibrosis" Int J Mol Sci (2023) 10.3390/ijms24097789

[17]

Read "Anti-inflammatory effects of GLP-1-based therapies beyond glucose control" Inflamm Mediat (2016) 10.1155/2016/3094642

[18]

Patti "Effect of semaglutide on subclinical atherosclerosis and cardiometabolic compensation: a real-world study in patients with type 2 diabetes" Biomedicines (2023) 10.3390/biomedicines11051362

[19]

Bray "Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials" Diabetes Obes Metab (2021) 10.1111/dom.14399

[20]

Page "The PRISMA 2020 statement: an updated guideline for reporting systematic reviews" Br Med J (2021) 10.1136/bmj.n7

[21]

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A C Sterne, Jelena Savović, Matthew J Page et al.

BMJ 2019 10.1136/bmj.l4898

[22]

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

Xiang Wan, Wenqian Wang, Jiming Liu et al.

BMC Medical Research Methodology 2014 10.1186/1471-2288-14-135

[23]

Conducting Meta-Analyses inRwith themetaforPackage

Wolfgang Viechtbauer

Journal of Statistical Software 2010 10.18637/jss.v036.i03

[24]

Ahmann "Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial" Diabetes Care (2018) 10.2337/dc17-0417

[25]

PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes

Vanita R. Aroda, Julio Rosenstock, Yasuo Terauchi et al.

Diabetes Care 2019 10.2337/dc19-0749

[26]

Rodbard "Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial" Diabetes Care (2019) 10.2337/dc19-0883

[27]

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

Ofri Mosenzon, Thalia Marie Blicher, Signe Rosenlund et al.

The Lancet Diabetes & Endocrinology 2019 10.1016/s2213-8587(19)30192-5

[28]

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John P.H. Wilding, Rachel L. Batterham, Salvatore Calanna et al.

New England Journal of Medicine 2021 10.1056/nejmoa2032183

[29]

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

Melanie Davies, Louise Færch, Ole K Jeppesen et al.

The Lancet 2021 10.1016/s0140-6736(21)00213-0

[30]

Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

Thomas A. Wadden, Timothy S. Bailey, Liana K. Billings et al.

JAMA 2021 10.1001/jama.2021.1831

[31]

Wharton "Two-year effect of semaglutide 2.4mg on control of eating in adults with overweight/obesity: STEP 5" Nat Med (2022) 10.38/s41591-022-02026-4

[32]

Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial

Takashi Kadowaki, Joakim Isendahl, Usman Khalid et al.

The Lancet Diabetes & Endocrinology 2022 10.1016/s2213-8587(22)00008-0

[33]

Rubino "Effect of weekly subcutaneous semaglutide vs. daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial" JAMA (2022) 10.1001/jama.2021.23619

[34]

Knop "Oral semaglutide 50mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial" Lancet (2023) 10.1016/s0140-6736(23)01185-6

[35]

Kosiborod "Semaglutide in patients with heart failure with preserved ejection fraction and obesity" N Engl J Med (2023) 10.1056/nejmoa2306963

[36]

Avan "Serum C-reactive protein in the prediction of cardiovascular diseases: overview of the latest clinical studies and public health practice" J Cell Physiol (2018) 10.1002/jcp.26791

[37]

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

Paul M Ridker, Deepak L Bhatt, Aruna D Pradhan et al.

The Lancet 2023 10.1016/s0140-6736(23)00215-5

[38]

C-Reactive Protein: Pathophysiology, Diagnosis, False Test Results and a Novel Diagnostic Algorithm for Clinicians

Dimitra S. Mouliou

Diseases 2023 10.3390/diseases11040132

[39]

Wang "The NLRP3 inflammasome: mechanism of action, role in disease and therapies" Mol Aspects Med (2020) 10.1016/j.mam.2020.100889

[40]

Ridker "From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection" Circ Res (2016) 10.1161/circresaha.115.306656

[41]

Amezcua-Castillo "C-reactive protein: the quintessential marker of systemic inflammation in coronary artery disease-advancing toward precision medicine" Biomedicines (2023) 10.3390/biomedicines11092444

[42]

Ridker "C-reactive protein levels and outcomes after statin therapy" N Engl J Med (2005) 10.1056/nejmoa042378

[43]

Ridker "Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial" Lancet (2018) 10.1016/s0140-6736(17)32814-3

[44]

Chen "A meta-analysis evaluating efficacy and safety of colchicine for prevention of major cardiovascular events in patients with coronary artery disease" Clin Res Cardiol (2023) 10.1007/s00392-023-02254-9

[45]

Nissen "Bempedoic acid and cardiovascular outcomes in statin-intolerant patients" N Engl J Med (2023) 10.1056/nejmoa2215024

[46]

Hattori "A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells" Diabetology (2010) 10.1007/s00125-010-1831-8

[47]

Krasner "Glucagon-like peptide-1 (GLP-1) analog liraglutide inhibits endothelial cell inflammation through a calcium and AMPK dependent mechanism" PLoS One (2014) 10.1371/journal.pone.0097554

[48]

Luo "Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation" Arch Biochem Biophys (2019) 10.1016/j.abb.2019.07.008

[49]

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE−/− and LDLr−/− Mice by a Mechanism That Includes Inflammatory Pathways

Günaj Rakipovski, Bidda Rolin, Jane Nøhr et al.

JACC: Basic to Translational Science 2018 10.1016/j.jacbts.2018.09.004

[50]

Giglio "Liraglutide increases Serum levels of MicroRNA-27b, −130a and −210 in patients with type 2 diabetes mellitus: a novel epigenetic effect" Metabolites (2020) 10.3390/metabo10100391

Showing 50 of 64 references

Metrics

39

Citations

64

References

Details

Published: Jul 05, 2024
Vol/Issue: 11
License: View

Authors

Juan Patricio Nogueira

A

Alfredo Matias Rodriguez-Granillo

L

Leandro Ezequiel Barbagelata

D

Daniel Siniawski

Cite This Article

Walter Masson, Martín Lobo, Juan Patricio Nogueira, et al. (2024). Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis. Frontiers in Cardiovascular Medicine, 11. https://doi.org/10.3389/fcvm.2024.1379189

Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis

You May Also Like